GSK plc

Equities

GSK

GB00BN7SWP63

Pharmaceuticals

Market Closed - London S.E. 09:05:12 16/05/2024 pm IST 5-day change 1st Jan Change
1,784 GBX -0.78% Intraday chart for GSK plc +0.56% +22.98%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
GSK to Sell Remaining Stake in Haleon Valued at Around $1.27 Billion -- Update DJ
GSK intends to sell its remaining stake in Haleon RE
GSK to Sell Stake in Haleon Valued at About $1.61 Billion DJ
GSK to sell remaining holding in spin-off Haleon AN
GSK Plans to Sell 385 Million Haleon Shares MT
GSK Plans to Sell About 385 Million Haleon Shares, Bloomberg Reports MT
GSK intends to sell its entire stake in Haleon RE
Europe struggles but record highs in New York AN
GSK Intends To Sell About 385 Mln Shares In Haleon RE
GSK PLC - GSK ANNOUNCES INTENTION TO SELL SHARES IN HALEON… RE
GSK invests £45 million and joins the Fleming Initiative CF
Health Sciences Authority Approves GSK's Arexvy, the First Respiratory Syncytial Virus Vaccine for Older Adults CI
Abu Dhabi to Host GSK's Regional Vaccine Hub Under New Health Partnership MT
GSK: towards the creation of a vaccine center in Abu Dhabi CF
DEPARTMENT OF HEALTH - ABU DHABI: DEPARTMENT OF HEALTH - ABU DHA… RE
US FDA declines to approve expanded use of Dynavax's hepatitis B vaccine RE
LBBW Raises GSK PT, Reiterates Buy Rating MT
DB and Berenberg raise Diploma price target AN
Jefferies Keeps GSK at Buy, Lifts PT MT
GSK : Deutsche Bank maintains a Buy rating ZD
GSK : Receives a Buy rating from Jefferies ZD
BAE Systems and Mondi cut to 'neutral' AN
France gets $16 billion of foreign investments as part of 'Choose France' event RE
French presidency: Amazon to announce new 1.2 bln euros investment in France RE
FRENCH PRESIDENCY: AMAZON TO ANNOUNCE EXTRA 1.2 BLN EUROS INVEST… RE
Chart GSK plc
More charts
GSK plc is a global biopharma company. The Company’s segments include Commercial Operations and Research and Development. It develops cancer medicines for patients, including ovarian cancer, endometrial cancer, and multiple myeloma. It has developed monoclonal antibodies to help treat different diseases. Its product areas include vaccines, specialty medicines, and general medicine. It is also focused on addressing the unmet treatment needs of patients with respiratory and inflammatory conditions. Its vaccine portfolio includes more than 20 vaccines that help to protect people from a range of diseases and infections, including meningitis, shingles and flu, among others. Its specialty medicines include medicines for immune-mediated conditions. Its specialty medicines are also engaged in developing medicines for respiratory disease and HIV. Its general medicines include inhaled medicines for asthma and chronic obstructive pulmonary disease, antibiotics, and medicines for skin diseases.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
21
Last Close Price
17.84 GBP
Average target price
20.32 GBP
Spread / Average Target
+13.95%
Consensus
  1. Stock Market
  2. Equities
  3. GSK Stock
  4. News GSK plc
  5. GSK Says US FDA Accepts Meningococcal Vaccine Candidate for Regulatory Review
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW